8-K: Vaxart Secures Additional $105.9 Million in BARDA Funding for Oral COVID-19 Vaccine Trial

Vaxart receives a $105.9 million funding boost from BARDA to advance its Phase 2b clinical trial of an oral COVID-19 vaccine candidate against an mRNA comparator.

Summary

• Vaxart, Inc. has entered into Modification No. 5 to its project agreement with Advanced Technology International, increasing funding for its Phase 2b clinical trial by approximately $105.9 million.
• The total funding allotted to the trial is now approximately $240.1 million.
• The trial will evaluate Vaxart's KP.2 oral vaccine candidate against an mRNA comparator directed against KP.2, involving 10,000 participants.
• The company has completed enrollment of a sentinel cohort of approximately 400 patients comparing its oral pill XBB candidate against an mRNA XBB comparator.
• An independent data safety monitoring board recommended the study to proceed without modifications based on initial safety assessment of 30-day data from the sentinel cohort.
• Vaxart is awaiting approval from BARDA to commence dosing in the trial.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant funding increase and progress in clinical trials, but tempered by the inherent risks and uncertainties associated with pharmaceutical development.

Positives

• The increased funding of $105.9 million strengthens Vaxart's financial position to execute the Phase 2b clinical trial.
• The trial design clarification focuses on the KP.2 variant, aligning with current COVID-19 strains.
• The completion of the sentinel cohort enrollment and positive DSMB recommendation indicate initial safety of the oral vaccine candidate.
• The trial will evaluate both efficacy and safety of Vaxart's oral vaccine candidate.

Risks

• Vaxart is awaiting approval from BARDA to commence dosing in the trial, which could introduce delays.
• The success of the trial is subject to risks and uncertainties associated with achieving milestones and deliverables under the Project Agreement.
• The company's continuing operating losses could impact its ability to execute the trial.
• The trial is subject to regulatory risks associated with clinical and regulatory development plans for its product candidates.

Future Outlook

The company's future outlook depends on the successful execution of the Phase 2b clinical trial and regulatory approvals. The company expects to derive data from ongoing and planned clinical trials and receive funding pursuant to the Project Agreement and/or the Modification.

Industry Context

The development of oral vaccines represents a potential advancement in vaccine technology, offering advantages in distribution and administration compared to traditional injectable vaccines. This announcement positions Vaxart as a key player in the development of novel vaccine platforms.

Comparison to Industry Standards

• The Phase 2b trial with 10,000 participants is a substantial investment, comparable to late-stage clinical trials conducted by companies like Pfizer and Moderna for their mRNA vaccines.
• Vaxart's focus on an oral vaccine differentiates it from companies primarily focused on injectable vaccines, such as Novavax and Johnson & Johnson.
• The comparison against an mRNA comparator aligns with industry standards for evaluating new vaccine candidates against established technologies.

Stakeholder Impact

• Shareholders will benefit from the increased funding and potential for successful vaccine development.
• Employees will be involved in the execution of the clinical trial and regulatory submissions.
• Customers (potential vaccine recipients) may benefit from a new oral vaccine option.
• Suppliers will be involved in providing materials and services for the clinical trial.
• Creditors may see increased confidence in Vaxart's financial stability.

Next Steps

• Vaxart is awaiting approval from BARDA to commence dosing in the trial.
• The company will continue to execute the Phase 2b clinical trial.
• Vaxart will submit regulatory filings to the FDA.

Key Dates